Table 3.
Comparison of the Clinicopathological Characteristics Among Patients with PFS ≤10.5 Months, PFS >10.5 Months and Non-PD Patients
| Characteristics | PD Group | Non-PD | P | |
|---|---|---|---|---|
| PFS ≤10.5 m | PFS >10.5 m | |||
| Case no. (row %) | 13 (20.0%) | 13 (20.0%) | 39 (60.0%) | |
| Age (years), mean ± SD | 67 ± 12 | 67 ± 11 | 64 ± 12 | 0.523 |
| Sex, female | 7 (53.8%) | 6 (46.2%) | 17 (43.6%) | 0.814 |
| BW (kg), mean ± SD | 59.5 ± 15.9 | 63.5 ± 12.4 | 64.6 ± 12.7 | 0.524 |
| Histology | 0.568 | |||
| Papillary carcinoma | 11 (84.6%) | 10 (76.9%) | 34 (87.2%) | |
| Follicular carcinoma | 2 (15.4%) | 2 (15.4%) | 5 (12.8%) | |
| Hürthle cell carcinoma | – | 1 (7.7%) | – | |
| ECOG change from baseline | 0.830 | |||
| Improved | 1 (7.7%) | 1 (7.7%) | 2 (5.1%) | |
| Unchanged | 11 (84.6%) | 11 (84.6%) | 30 (76.9%) | |
| Worsened | 1 (7.7%) | 1 (7.7%) | 7 (17.9%) | |
| Lesion involvement | ||||
| Lung | 11 (84.6%) | 12 (92.3%) | 31 (79.5%) | 0.733 |
| Bone | 9 (69.2%) | 6 (46.2%) | 10 (25.6%) a | 0.016 |
| Neck | 9 (69.2%) | 8 (61.5%) | 21 (53.8%) | 0.689 |
| Other sites | 6 (46.2%) | 8 (61.5%) | 6 (15.4%) b | 0.003 |
| Cumulative radioiodine dose, median (IQR) | 375 (237.5–487.5) | 570 (412.5–612.5) | 400 (300–500) | 0.135 |
| Subgroup of RRDTC | ||||
| ≥600mCi | 3 (23.1%) | 6 (46.2%) | 4 (10.3%) b | 0.016 |
| Presence of any RAI refractory lesion | 8 (61.5%) | 9 (69.2%) | 28 (71.8%) | 0.812 |
| Disease progression in RAI avid lesion | 9 (69.2%) | 5 (38.5%) | 14 (35.9%) | 0.129 |
| Structural progression before lenvatinib | 13 (100.0%) | 12 (92.3%) | 28 (71.8%) a | 0.046 |
| Previous another TKI use before lenvatinib | 4 (30.8%) | 4 (30.8%) | 6 (15.4%) | 0.286 |
Notes: P-value were estimated using Fisher’s exact test and kruskal–Wallis test appropriately. aNon-PD group obtained statistically significant lower proportion compared to group of PFS ≤10.5 months. bNon-PD group obtained statistically significant lower proportion compared to group of PFS >10.5 months.
Abbreviations: SD, standard deviation; IQR, interquartile range; RAI, radioiodine; RRDTC, radioiodine refractory differentiated thyroid carcinoma.